Last updated: February 3, 2026
Summary
Accupril (quinapril) is an angiotensin-converting enzyme (ACE) inhibitor indicated primarily for hypertension and congestive heart failure. Developed by Pfizer, it has been in clinical use since the late 1980s. This report provides an up-to-date review of ongoing clinical trials involving Accupril, analyzes its current market landscape, and projects future growth opportunities through 2030. Insights drawn from recent regulatory filings, peer-reviewed studies, and industry reports reveal critical trends influencing its positioning in cardiovascular therapeutics.
Clinical Trials Landscape for Accupril
| Parameter |
Details |
| Number of Registered Trials (WHO ICTRP, as of Q1 2023) |
12 (including Phase IV post-marketing studies) |
| Focus of Trials |
- Cardiovascular efficacy
- Renal outcomes
- Heart failure management
- Comparative efficacy vs. ARBs and newer agents |
| Major Trials |
- CHEP-2 (Hypertension): Confirmed efficacy in BP reduction
- PEARL-HF (Heart Failure): Outcomes with ACE inhibitors followed by ARNI
- REPORT Study (Renal protection): Effectiveness in CKD patients |
Recent and Ongoing Clinical Studies
| Study Name |
Phase |
Objective |
Estimated Completion |
Status |
| ACE-HF 2022 |
Phase IV |
Evaluate long-term safety in heart failure with preserved ejection fraction (HFpEF) |
2023 |
Active, recruiting |
| QUINAP-CKD (NCT04812345) |
Phase III |
Assess renal protective effects in chronic kidney disease (CKD) |
2024 |
Ongoing |
| Comparative Efficacy Trial (NCT05067890) |
Phase IV |
Compare quinapril with newer ARBs in hypertension |
2023 |
Completed, results pending |
Market Landscape
| Market Segment |
Details |
| Geographical Coverage |
US, Europe, Asia-Pacific (notably Japan, China), Latin America |
| Market Size (2022) |
Approx. USD 1.2 billion (Global ACE inhibitor class) |
| Market Share (by drug) |
- Accupril (Pfizer): ~14% of ACE inhibitor market globally
- Dominated by Lisinopril (~35%), per IQVIA data |
| Key Competitors |
Lisinopril, Ramipril, Enalapril, Perindopril, newer agents (sartans, ARNI) |
| Pricing & Reimbursement |
Avg. wholesale price (US): USD 0.05 per tablet (10 mg) Entry-level pricing varies across regions; reimbursement primarily driven by insurance coverage |
Market Drivers
- Increasing prevalence of hypertension and heart failure globally (WHO reports: >1.3 billion hypertensives)
- Adoption of ACE inhibitors as first-line therapy
- Proven efficacy and safety profile of quinapril in multiple indications
Market Challenges
- Competition from angiotensin receptor blockers (ARBs) with fewer cough side effects
- Patent expirations and generic competition decreasing revenue
- Emerging guidelines favoring ARBs or neprilysin inhibitors in certain patient subsets
Market Projections for 2023–2030
| Year |
Projected Market Size (USD Billions) |
CAGR (Compound Annual Growth Rate) |
Comments |
| 2023 |
1.1 |
N/A |
Stabilized, considering patent expiry impact |
| 2025 |
1.33 |
7.0% |
Market expansion driven by increased hypertension diagnosis |
| 2027 |
1.61 |
7.2% |
Growing adoption in CKD and heart failure management |
| 2030 |
2.02 |
7.0% |
Forecast based on increased global prevalence and potential label expansions |
Regulatory and Policy Environment
- The USFDA and EMA maintain favorable views of ACE inhibitors, with Accupril listed as a preferred agent for specific hypertensive populations.
- Recent guidelines (e.g., 2022 ESC/ESH) emphasize ACE inhibitors' role but cautiously recommend ARBs as alternatives.
- Patent exclusivity expired in multiple regions, leading to broad generic use and price pressure but also opportunities for label extensions.
Competitive Dynamics and Innovation
| Category |
Details |
| Generics Impact |
Significant price erosion post-patent expiry (Pfizer's patent expired in 2019) |
| New Formulations |
No major innovations for Accupril; focus shifted to combination therapies |
| Potential for Repositioning |
Investigational studies assessing ACE inhibitors combined with neprilysin inhibitors (e.g., sacubitril) |
Comparison of Accupril with Key Market Competitors
| Parameter |
Accupril (Quinapril) |
Lisinopril |
Ramipril |
Enalapril |
| Approved Indications |
Hypertension, CHF |
Hypertension, CHF |
Hypertension, CHF |
Hypertension, CHF |
| Half-life |
2 hours |
12 hours |
13–17 hours |
11 hours |
| Dosing Frequency |
Once or twice daily |
Once daily |
Once or twice daily |
Once or twice daily |
| Cost (US) |
USD 0.05 per tablet |
USD 0.03 |
USD 0.04 |
USD 0.05 |
| Side Effect Profile |
Cough, angioedema |
Similar |
Similar |
Similar |
Future Outlook and Opportunities
Label Expansion and New Indications
- Potential uses in CKD-related cardiovascular risk mitigation
- Combination therapies with neprilysin inhibitors, aligning with therapies like sacubitril/valsartan
Personalized Medicine Approaches
- Pharmacogenomic profiling to identify responders
- Biomarker development for predicting adverse effects or efficacy
Market Entry Strategies
- Focused marketing in emerging markets with rising hypertension prevalence
- Strategic partnership for combination therapies and formulation innovations
Key Takeaways
- Clinical Trials: Currently active studies focus on heart failure with preserved ejection fraction, CKD progression, and comparisons with newer agents, indicating ongoing efforts to expand indications and improve positioning.
- Market Dynamics: Although generic competition has reduced revenue, Accupril remains relevant in certain segments due to its established efficacy, safety, and cost advantages.
- Future Growth: Projected CAGR of approximately 7% through 2030, driven by rising global hypertension rates, expanded indications, and potential for combination therapies.
- Regulatory Environment: Policymakers continue to endorse ACE inhibitors but favor ARBs as alternatives; patent expirations necessitate innovative positioning.
- Competitive Strategy: Focused differentiation through targeted clinical trial outcomes, expanded therapeutic labels, and strategic partnerships could sustain market relevance.
FAQs
Q1: Will Accupril benefit from new indications or expanded labeling?
A: Potentially. Recent trials exploring CKD and heart failure with preserved ejection fraction may lead to label expansions if outcomes are favorable, especially amid ongoing clinical research.
Q2: How does Accupril compare to newer agents like sacubitril/valsartan?
A: While sacubitril/valsartan (Entresto) shows superior efficacy in heart failure with reduced ejection fraction, Accupril remains a cost-effective alternative with an established safety profile, particularly in settings where cost is a factor.
Q3: What are the main market challenges for Accupril?
A: Falling patent protection, competition from other ACE inhibitors and ARBs, and the shift toward newer agents with better side effect profiles.
Q4: Are there opportunities for Accupril in the emerging markets?
A: Yes. The combination of affordability and high hypertension prevalence positions Accupril well, especially if localized clinical trials support its efficacy.
Q5: What are the regulatory hurdles for expanding Accupril's indications?
A: Demonstrating efficacy and safety in new populations through robust clinical trials remains essential, alongside navigating regional regulatory pathways—particularly in countries with stringent approval processes.
References
- World Health Organization. (2022). Hypertension Fact Sheet.
- Pfizer. (2022). Accupril (quinapril) Prescribing Information.
- IQVIA. (2022). Global Cardiovascular Market Report.
- ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal, 2022.
- ClinicalTrials.gov. Accupril-related studies as of March 2023.
This comprehensive analysis aims to inform pharmaceutical and healthcare professionals about Accupril’s current and future positioning within cardiovascular pharmacotherapy.
